Skip to content

Study · Randomized controlled trial · 2010

5 results

Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial.

Strowitzki T, Marr J, Gerlinger C, Faustmann T, Seitz C

Human reproduction (Oxford, England)19 Jan 2010Cited by 217 (Europe PMC)

PMID20089522 (opens in a new tab)DOI10.1093/humrep/dep469 (opens in a new tab)PepBankPUB-20089522
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women with endometriosis, pelvic pain reductions were equivalent: 46.0 mm with leuprolide versus 47.5 mm with dienogest at Week 24.

    In plain wordsIn women with endometriosis, pain reductions were equivalent: 46.0 mm with leuprolide versus 47.5 mm with dienogest at Week 24.

    Peptide
    Leuprolide
    Outcome
    No significant changePelvic pain VAS reduction
    Study

    n: not reported in source

    Comparator
    Dienogest 2 mg/day
    Analysis
    Primary
    Outcome group
    Pain · Reproductive and sexual health
    Studied dose
    3.75 mg every 4 weeks · intramuscular depot injection · 24 weeksAs given in this study (human).

    Measurements

    Absolute reduction in pelvic pain VAS
    46 mm
    leuprolide acetate, baseline to Week 24
    Absolute reduction in pelvic pain VAS
    47.5 mm
    dienogest comparator, baseline to Week 24

    Source sentences

    Summary
    Absolute reductions in VAS score from baseline to Week 24 were 47.5 mm with dienogest and 46.0 mm with LA, demonstrating the equivalence of dienogest relative to LA.
    1 context sentence
    Summary · context
    Patients with confirmed endometriosis were randomized to treatment with dienogest (2 mg/day, orally) or LA (3.75 mg, depot i.m. injection, every 4 weeks) for 24 weeks.
  2. 02HumanRandomized controlled trialSafety outcome

    In women with endometriosis, hypoestrogenic effects including hot flushes occurred more frequently with leuprolide than dienogest.

    In plain wordsIn women with endometriosis, effects of low estrogen, including hot flushes, occurred more frequently with leuprolide than dienogest.

    Peptide
    Leuprolide
    Outcome
    IncreaseHypoestrogenic effects including hot flushes
    Study

    n: not reported in source

    Comparator
    Dienogest 2 mg/day
    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    3.75 mg every 4 weeks · intramuscular depot injection · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Hypoestrogenic effects (e.g. hot flushes) were reported less frequently in the dienogest group.
    1 context sentence
    Summary · context
    Patients with confirmed endometriosis were randomized to treatment with dienogest (2 mg/day, orally) or LA (3.75 mg, depot i.m. injection, every 4 weeks) for 24 weeks.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In women with endometriosis, leuprolide suppressed bleeding episodes more than dienogest.

    In plain wordsIn women with endometriosis, leuprolide suppressed bleeding episodes more than dienogest.

    Peptide
    Leuprolide
    Outcome
    DecreaseBleeding episodes
    Study

    n: not reported in source

    Comparator
    Dienogest 2 mg/day
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3.75 mg every 4 weeks · intramuscular depot injection · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    As expected, bleeding episodes were suppressed less with dienogest than with LA.
    1 context sentence
    Summary · context
    Patients with confirmed endometriosis were randomized to treatment with dienogest (2 mg/day, orally) or LA (3.75 mg, depot i.m. injection, every 4 weeks) for 24 weeks.
  4. 04HumanRandomized controlled trialSafety outcome

    In women with endometriosis, lumbar bone mineral density changed by -4.04% with leuprolide versus +0.25% with dienogest (P = 0.0003).

    In plain wordsIn women with endometriosis, lumbar bone density changed by -4.04% with leuprolide versus +0.25% with dienogest.

    Peptide
    Leuprolide
    Outcome
    DecreaseLumbar bone mineral density
    Study

    n: not reported in source

    Comparator
    Dienogest 2 mg/day
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    3.75 mg every 4 weeks · intramuscular depot injection · 24 weeksAs given in this study (human).

    Measurements

    Change in mean lumbar BMD
    −4.04%
    leuprolide acetate, screening to final visit
    Change in mean lumbar BMD
    0.25%
    dienogest comparator, screening to final visit
    P value
    0.0003
    between groups

    Source sentences

    Summary
    Changes in mean lumbar BMD between screening and final visit were +0.25% with dienogest and -4.04% with LA subgroups (P = 0.0003).
    1 context sentence
    Summary · context
    Patients with confirmed endometriosis were randomized to treatment with dienogest (2 mg/day, orally) or LA (3.75 mg, depot i.m. injection, every 4 weeks) for 24 weeks.
  5. 05HumanRandomized controlled trialSafety outcome

    In women with endometriosis, bone resorption markers increased with leuprolide but not dienogest.

    In plain wordsIn women with endometriosis, markers of bone breakdown increased with leuprolide but not dienogest.

    Peptide
    Leuprolide
    Outcome
    IncreaseBone resorption markers
    Study

    n: not reported in source

    Comparator
    Dienogest 2 mg/day
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    3.75 mg every 4 weeks · intramuscular depot injection · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Markers of bone resorption increased with LA but not dienogest.
    1 context sentence
    Summary · context
    Patients with confirmed endometriosis were randomized to treatment with dienogest (2 mg/day, orally) or LA (3.75 mg, depot i.m. injection, every 4 weeks) for 24 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.